

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2015

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended
		30-06-2015	31-03-2015	30-06-2014	31-03-2015
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	a. Net sales (Net of excise duty)	27,914.93	24,975.71	25,671.21	1,03,813.61
	b. Other Operating Income	505.92	533.52	589.07	2,328.51
	Total Income from Operations (Net) (a+b)	28,420.85	25,509.23	26,260.28	1,06,142.12
2	Expenses				
	a. Cost of materials consumed	9,022.98	8,705.22	8,338.64	34,158.73
	b. Purchases of stock-in-trade	2,309.10	1,906.91	2,402.03	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	599.54	(277.20)	437.46	(68.24)
	d. Employees benefits expense	4,097.01	3,858.93	3,718.27	14,681.81
	e. Depreciation and amortization expense	977.00	757.99	990.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	118.72	39.94	(49.45)	58.16
	g. Other Expenses	7,320.63	7,053.92	6,578.02	28,633.60
	Total Expenses	24,444.98	22,045.71	22,414.97	90,233.71
3	Profit from Operations before Other Income, Finance Cost (1-2)	3,975.87	3,463.52	3,845.31	15,908.41
4	Other Income	429.71	150.48	173.96	1,040.88
5	Profit before Finance Cost (3+4)	4,405.58	3,614.00	4,019.27	16,949.29
6	Finance Cost	171.03	22.33	132.57	665.01
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	4,234.55	3,591.67	3,886.70	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	398.64	280.94	368.77	(373.86)
9	Profit before Tax (7+8)	4,633.19	3,872.61	4,255.47	15,910.42
10	Tax expenses	1,205.00	1,298.97	1,076.37	4,552.17
11	Net Profit/(Loss) after Tax (9-10)	3,428.19	2,573.64	3,179.10	11,358.25
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.16	1,696.16	1,695.40	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	99,934.99
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	4.04	3.04	3.75	13.40
	(2) Diluted	4.04	3.03	3.75	13.39

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

Sl. No.	PART II - Particulars	Quarter ended			Year ended
		30-06-2015	31-03-2015	30-06-2014	31-03-2015
A	PARTICULARS OF SHAREHOLDING	Unaudited	Audited	Unaudited	Audited
1	Public Shareholding				
	- Number of Shares	3,75,02,888	3,75,02,888	3,74,53,963	3,75,02,888
	- Percentage of shareholding	44.22	44.22	44.18	44.22
2	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	4,73,05,337	4,73,05,337	4,73,15,787	4,73,05,337
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.78	55.78	55.82	55.78

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/06/2015
Pending at the beginning of the quarter	0
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	0

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on August 5, 2015.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on June 30, 2015.
- The figures for the quarter ended on March 31, 2015 are the balancing figures between audited figures in respect of the full financial year ended on March 31, 2015 and the published year-to-date figures upto the third quarter ended on December 31, 2014.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's figures have been regrouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai

Date : August 5, 2015

J.B.Mody

Chairman & Managing Director

REPORT OF THE LIMITED REVIEW

To
The Board of Directors of
J. B. CHEMICALS & PHARMACEUTICALS LTD.

We have reviewed the accompanying statement of unaudited financial results of **J. B. CHEMICALS & PHARMACEUTICALS LTD.** for the period ended 30th June, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards as per section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rule, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **J. K. Shah & Co.**
Chartered Accountants
Firm Regn. No. 109606W



J.K. Shah
Partner
Membership No. 03662



Place: Mumbai
Date: 05th August, 2015

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com


CIN : L24390MH1976PLC019380

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2015

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended
		30-06-2015	31-03-2015	30-06-2014	31-03-2015
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	a. Net sales (Net of excise duty)	27,914.93	24,975.71	25,671.21	1,03,813.61
	b. Other Operating Income	505.92	533.52	589.07	2,328.51
	Total Income from Operations (Net) (a+b)	28,420.85	25,509.23	26,260.28	1,06,142.12
2	Expenses				
	a. Cost of materials consumed	9,022.98	8,705.22	8,338.64	34,158.73
	b. Purchases of stock-in-trade	2,309.10	1,906.91	2,402.03	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	599.54	(277.20)	437.46	(68.24)
	d. Employees benefits expense	4,097.01	3,858.93	3,718.27	14,681.81
	e. Depreciation and amortization expense	977.00	757.99	990.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	118.72	39.94	(49.45)	58.16
	g. Other Expenses	7,320.63	7,053.92	6,578.02	28,633.60
	Total Expenses	24,444.98	22,045.71	22,414.97	90,233.71
3	Profit from Operations before Other Income, Finance Cost (1-2)	3,975.87	3,463.52	3,845.31	15,908.41
4	Other Income	429.71	150.48	173.96	1,040.88
5	Profit before Finance Cost (3+4)	4,405.58	3,614.00	4,019.27	16,949.29
6	Finance Cost	171.03	22.33	132.57	665.01
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	4,234.55	3,591.67	3,886.70	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	398.64	280.94	368.77	(373.86)
9	Profit before Tax (7+-8)	4,633.19	3,872.61	4,255.47	15,910.42
10	Tax expenses	1,205.00	1,298.97	1,076.37	4,552.17
11	Net Profit/(Loss) after Tax (9-10)	3,428.19	2,573.64	3,179.10	11,358.25
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.16	1,696.16	1,695.40	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	99,934.99
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	4.04	3.04	3.75	13.40
	(2) Diluted	4.04	3.03	3.75	13.39

JSW



JSW

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380


Sl. No.	PART II - Particulars	Quarter ended			Year ended
		30-06-2015	31-03-2015	30-06-2014	31-03-2015
A	PARTICULARS OF SHAREHOLDING	Unaudited	Audited	Unaudited	Audited
1	Public Shareholding				
	- Number of Shares	3,75,02,888	3,75,02,888	3,74,53,963	3,75,02,888
	- Percentage of shareholding	44.22	44.22	44.18	44.22
2	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	4,73,05,337	4,73,05,337	4,73,15,787	4,73,05,337
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.78	55.78	55.82	55.78

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/06/2015
Pending at the beginning of the quarter	0
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	0

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on August 5, 2015.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on June 30, 2015.
- The figures for the quarter ended on March 31, 2015 are the balancing figures between audited figures in respect of the full financial year ended on March 31, 2015 and the published year-to-date figures upto the third quarter ended on December 31, 2014.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's figures have been regrouped/re-stated, wherever necessary.



Place : Mumbai
Date : August 5, 2015

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody
Chairman & Managing Director